vs
CHOICEONE FINANCIAL SERVICES INC（COFS）とMESA LABORATORIES INC（MLAB）の財務データ比較。上の社名をクリックして会社を切り替えられます
MESA LABORATORIES INCの直近四半期売上が大きい（$65.1M vs $42.9M、CHOICEONE FINANCIAL SERVICES INCの約1.5倍）。CHOICEONE FINANCIAL SERVICES INCの前年同期比売上増加率が高い（76.4% vs 3.6%）。CHOICEONE FINANCIAL SERVICES INCの直近四半期フリーキャッシュフローが多い（$25.2M vs $18.0M）。過去8四半期でCHOICEONE FINANCIAL SERVICES INCの売上複合成長率が高い（15.0% vs 5.1%）
ChoiceOne Financial Services Incは米国の地域金融持株会社で、傘下の銀行子会社を通じて主にミシガン州の個人消費者、中小企業、企業顧客に貯蓄口座、ローン、資産管理、保険などの個人向け・商用銀行サービスを提供しています。
メサラボラトリーズ社は、品質管理、校正、モニタリング向け専門機器及び関連サービスの開発・製造・販売を事業としています。医療、製薬、食品飲料、産業衛生、環境試験分野を中心に、世界中の顧客の規制遵守と運用安全のニーズに応えています。
COFS vs MLAB — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $42.9M | $65.1M |
| 純利益 | — | $3.6M |
| 粗利率 | — | 64.2% |
| 営業利益率 | 39.1% | 12.2% |
| 純利益率 | — | 5.6% |
| 売上前年比 | 76.4% | 3.6% |
| 純利益前年比 | — | 316.6% |
| EPS（希薄化後） | $1.43 | $0.65 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $42.9M | $65.1M | ||
| Q3 25 | $61.8M | $60.7M | ||
| Q2 25 | $60.4M | $59.5M | ||
| Q1 25 | $44.9M | $62.1M | ||
| Q4 24 | $24.3M | $62.8M | ||
| Q3 24 | $36.6M | $57.8M | ||
| Q2 24 | $34.0M | $58.2M | ||
| Q1 24 | $32.5M | $58.9M |
| Q4 25 | — | $3.6M | ||
| Q3 25 | $14.7M | $2.5M | ||
| Q2 25 | $13.5M | $4.7M | ||
| Q1 25 | $-13.9M | $-7.1M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | $7.3M | $3.4M | ||
| Q2 24 | $6.6M | $3.4M | ||
| Q1 24 | $5.6M | $-254.6M |
| Q4 25 | — | 64.2% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | — | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 64.0% | ||
| Q1 24 | — | 62.1% |
| Q4 25 | 39.1% | 12.2% | ||
| Q3 25 | 29.6% | 7.8% | ||
| Q2 25 | 27.6% | 5.1% | ||
| Q1 25 | -39.2% | 2.4% | ||
| Q4 24 | 36.1% | 9.2% | ||
| Q3 24 | 25.4% | 6.1% | ||
| Q2 24 | 24.0% | 9.6% | ||
| Q1 24 | 21.1% | -460.6% |
| Q4 25 | — | 5.6% | ||
| Q3 25 | 23.7% | 4.1% | ||
| Q2 25 | 22.4% | 8.0% | ||
| Q1 25 | -31.0% | -11.4% | ||
| Q4 24 | — | -2.7% | ||
| Q3 24 | 20.1% | 5.9% | ||
| Q2 24 | 19.4% | 5.8% | ||
| Q1 24 | 17.3% | -432.2% |
| Q4 25 | $1.43 | $0.65 | ||
| Q3 25 | $0.97 | $0.45 | ||
| Q2 25 | $0.90 | $0.85 | ||
| Q1 25 | $-1.29 | $-1.30 | ||
| Q4 24 | $0.79 | $-0.31 | ||
| Q3 24 | $0.85 | $0.63 | ||
| Q2 24 | $0.87 | $0.62 | ||
| Q1 24 | $0.74 | $-47.26 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $88.0M | $29.0M |
| 総負債低いほど良い | — | $68.4M |
| 株主資本純資産 | $465.4M | $186.7M |
| 総資産 | $4.4B | $434.8M |
| 負債/資本比率低いほどレバレッジが低い | — | 0.37× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $88.0M | $29.0M | ||
| Q3 25 | $99.0M | $20.4M | ||
| Q2 25 | $156.3M | $21.3M | ||
| Q1 25 | $139.4M | $27.3M | ||
| Q4 24 | $96.8M | $27.3M | ||
| Q3 24 | $145.9M | $24.3M | ||
| Q2 24 | $101.0M | $28.5M | ||
| Q1 24 | $150.1M | $28.2M |
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
| Q4 25 | $465.4M | $186.7M | ||
| Q3 25 | $449.6M | $178.5M | ||
| Q2 25 | $431.8M | $172.5M | ||
| Q1 25 | $427.1M | $159.8M | ||
| Q4 24 | $260.4M | $155.2M | ||
| Q3 24 | $247.7M | $161.5M | ||
| Q2 24 | $214.5M | $150.7M | ||
| Q1 24 | $206.8M | $145.4M |
| Q4 25 | $4.4B | $434.8M | ||
| Q3 25 | $4.3B | $430.4M | ||
| Q2 25 | $4.3B | $435.7M | ||
| Q1 25 | $4.3B | $433.3M | ||
| Q4 24 | $2.7B | $433.3M | ||
| Q3 24 | $2.7B | $454.1M | ||
| Q2 24 | $2.7B | $440.4M | ||
| Q1 24 | $2.7B | $446.8M |
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $31.8M | $18.8M |
| フリーキャッシュフロー営業CF - 設備投資 | $25.2M | $18.0M |
| FCFマージンFCF / 売上 | 58.7% | 27.7% |
| 設備投資強度設備投資 / 売上 | 15.4% | 1.1% |
| キャッシュ転換率営業CF / 純利益 | — | 5.17× |
| 直近12ヶ月FCF直近4四半期 | $38.5M | $37.9M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $31.8M | $18.8M | ||
| Q3 25 | $15.3M | $8.2M | ||
| Q2 25 | $9.0M | $1.9M | ||
| Q1 25 | $-6.5M | $12.7M | ||
| Q4 24 | $47.1M | $18.1M | ||
| Q3 24 | $-7.4M | $5.3M | ||
| Q2 24 | $15.7M | $10.7M | ||
| Q1 24 | $15.3M | $12.9M |
| Q4 25 | $25.2M | $18.0M | ||
| Q3 25 | $13.7M | $7.1M | ||
| Q2 25 | $6.9M | $884.0K | ||
| Q1 25 | $-7.3M | $11.9M | ||
| Q4 24 | $45.4M | $17.3M | ||
| Q3 24 | $-7.6M | $3.5M | ||
| Q2 24 | $15.3M | $9.9M | ||
| Q1 24 | $15.0M | $12.3M |
| Q4 25 | 58.7% | 27.7% | ||
| Q3 25 | 22.1% | 11.7% | ||
| Q2 25 | 11.4% | 1.5% | ||
| Q1 25 | -16.3% | 19.2% | ||
| Q4 24 | 186.4% | 27.6% | ||
| Q3 24 | -20.8% | 6.0% | ||
| Q2 24 | 44.8% | 16.9% | ||
| Q1 24 | 46.2% | 21.0% |
| Q4 25 | 15.4% | 1.1% | ||
| Q3 25 | 2.6% | 1.8% | ||
| Q2 25 | 3.4% | 1.7% | ||
| Q1 25 | 1.9% | 1.2% | ||
| Q4 24 | 7.0% | 1.3% | ||
| Q3 24 | 0.7% | 3.1% | ||
| Q2 24 | 1.4% | 1.5% | ||
| Q1 24 | 1.0% | 0.9% |
| Q4 25 | — | 5.17× | ||
| Q3 25 | 1.04× | 3.32× | ||
| Q2 25 | 0.66× | 0.40× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.00× | 1.54× | ||
| Q2 24 | 2.39× | 3.17× | ||
| Q1 24 | 2.72× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
COFS
セグメントデータなし
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
